Esperion news

Esperion Therapeutics is a biopharmaceutical company that focuses on developing and commercializing innovative treatments for patients with high cholesterol and other cardiovascular diseases. Here are some recent news and updates about Esperion:

Recent News:

  1. Bempedoic acid receives FDA approval: In November 2020, the US Food and Drug Administration (FDA) approved bempedoic acid, Esperion's lead product candidate, for the treatment of heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) in adults.
  2. Commercial launch of bempedoic acid: Esperion launched bempedoic acid in the US in December 2020, under the brand name Nexletorodipine.
  3. Partnership with AstraZeneca: In October 2020, Esperion announced a partnership with AstraZeneca to develop and commercialize bempedoic acid in Japan and other countries outside the US.
  4. Phase 3 clinical trial results: In September 2020, Esperion announced positive results from its Phase 3 clinical trial of bempedoic acid in patients with HeFH or ASCVD.

Upcoming Events:

  1. American Heart Association (AHA) Scientific Sessions: Esperion is scheduled to present data on bempedoic acid at the AHA Scientific Sessions in November 2021.
  2. Cardiovascular Research Technologies (CRT) Meeting: Esperion will present data on bempedoic acid at the CRT Meeting in June 2021.

Recent Financials:

  1. Q4 2020 financial results: Esperion reported a net loss of $44.6 million for the fourth quarter of 2020, compared to a net loss of $34.4 million for the same period in 2019.
  2. 2020 financial results: Esperion reported a net loss of $143.4 million for the full year 2020, compared to a net loss of $114.4 million for 2019.

Pipeline:

  1. Bempedoic acid: Esperion's lead product candidate, bempedoic acid, is a first-in-class, oral, once-daily treatment for patients with high cholesterol and other cardiovascular diseases.
  2. ETC-1002: Esperion is developing ETC-1002, a novel, oral, once-daily treatment for patients with hypertriglyceridemia and other cardiovascular diseases.

Please note that this information is subject to change and may not be comprehensive. For the latest news and updates on Esperion Therapeutics, I recommend visiting the company's website or following reputable news sources.